Treats urinary tract infections. ANDA 77025, held by Aurobindo Pharma USA. Nitrofurantoin, Macrocrystalline.
As of Nov 16, 2026, ANDA 77025 (Nitrofurantoin), held by Aurobindo Pharma USA, was first approved by FDA on Aug 18, 2004, with 6 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE: Nitrofurantoin capsules (macrocrystals) are specifically indicated for the treatment of urinary tract infections when due to susceptible strains of Escherichia coli, enterococci, Staphylococcus aureus, and certain susceptible strains of Klebsiella and Enterobacter species. Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 18, 2004 | Original application | Approved | None posted |
| Nitrofurantoin100MG · capsule;oral | Nitrofurantoin, Macrocrystalline | Rx |
| Nitrofurantoin25MG · capsule;oral | Nitrofurantoin, Macrocrystalline | Rx |
| Oct 2, 2024 | Supplement 9Manufacturing | Approved | None posted |
| Dec 11, 2023 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jan 15, 2015 | Supplement 5Labeling · Standard review | Approved | None posted |
| Nov 14, 2012 | Supplement 4Labeling · Standard review | Approved | None posted |
| Sep 18, 2012 | Supplement 3Labeling · Standard review | Approved | None posted |
| Nov 2, 2011 | Supplement 2Manufacturing | Approved | None posted |
| Aug 18, 2004 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters